key: cord-0903089-dxf3hgq2
authors: Aldea, D.; Martinez, T.; Miller, S.; Miklin, D.; Depasquale, E.; Vaidya, A.; Wolfson, A.
title: Transplant Recipient Characteristics in COVID vs Non COVID Cause of Death
date: 2022-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2022.01.1581
sha: f69000a4460b6370f73ab44665c5251065e13145
doc_id: 903089
cord_uid: dxf3hgq2

Purpose The purpose of this study is to compare patient characteristics of those who died from Covid-19 compared to death from all other causes. Methods The UNOS registry was queried to compare transplant recipients who died of Covid (n=300) vs non-Covid causes (n=5,644) from 2018 to 2021. Patient characteristics including age, sex, ethnicity, smoking, medical comorbidities, and time of transplant hemodynamics were evaluated. Baseline characteristics were compared using the Mann Whitney U test and Chi square test as appropriate. Survival was compared using Kaplan-Meier survival analysis. Results The population who died from Covid was significantly older (56.6y vs 49.8y, p <0.001), had a higher percentage of males (79.3% vs 74.3%, p=0.049), had a higher incidence of diabetes (39.1% vs 27.8%, p<0.001), increased incidence of smoking (53.7% vs 42% p<0.001), and had a higher cardiac output (4.7L/min vs 4.5L/min, p=0.032). Causians had significantly lower incidence of death from Covid (62.7% vs 67.2%, p=0.031). Donor age, waiting times, baseline renal function, ischemic times, and cardiopulmonary support time did not differ significantly between the two populations. Conclusion Widely studied risk factors for Covid pneumonia mortality such as age, male sex, diabetes, and smoking were consistent in the post heart transplant population. Communities of color were disproportionately affected by Covid. Furthermore, Covid deaths were not associated with inferior cardiac characteristics at time of transplant. More investigation is warranted to investigate the effect of more widely available immunologic and pharmacological therapies on high-risk subpopulations following heart transplant.

Purpose: The purpose of this study is to compare patient characteristics of those who died from Covid-19 compared to death from all other causes. Methods: The UNOS registry was queried to compare transplant recipients who died of Covid (n=300) vs non-Covid causes (n=5,644) from 2018 to 2021. Patient characteristics including age, sex, ethnicity, smoking, medical comorbidities, and time of transplant hemodynamics were evaluated. Baseline characteristics were compared using the Mann Whitney U test and Chi square test as appropriate. Survival was compared using Kaplan-Meier survival analysis. Results: The population who died from Covid was significantly older (56.6y vs 49.8y, p <0.001), had a higher percentage of males (79.3% vs 74.3%, p=0.049), had a higher incidence of diabetes (39.1% vs 27.8%, p<0.001), increased incidence of smoking (53.7% vs 42% p<0.001), and had a higher cardiac output (4.7L/min vs 4.5L/min, p=0.032). Causians had significantly lower incidence of death from Covid (62.7% vs 67.2%, p=0.031). Donor age, waiting times, baseline renal function, ischemic times, and cardiopulmonary support time did not differ significantly between the two populations. Conclusion: Widely studied risk factors for Covid pneumonia mortality such as age, male sex, diabetes, and smoking were consistent in the post heart transplant population. Communities of color were disproportionately affected by Covid. Furthermore, Covid deaths were not associated with inferior cardiac characteristics at time of transplant. More investigation is warranted to investigate the effect of more widely available immunologic and pharmacological therapies on high-risk subpopulations following heart transplant. Purpose: Cytomegalovirus (CMV) infection commonly affects heart transplants (HT). Guidelines recommend 3-6 months of prophylaxis (ppx) for primary mismatch (D+/R-) with (val)ganciclovir. We sought to assess the frequency of CMV infection subsequent to our protocol change where ppx was decreased from 12 to 6 months. Methods: This was a single-center, retrospective study of adults who underwent CMV D+/R-HT from 2009-2020 with a follow up of 18 months (5 patients had shorter follow up but all developed CMV infection and were included for analysis). Results: Overall, 76 HT recipients met inclusion criteria. Patient characteristics are shown in Table 1 . In the 6 and 12 month ppx protocols, there were 23 (71.9%) and 12 (27.3%) CMV infection episodes, respectively. Of these infections, 46.9% and 9.1% of HT were hospitalized. Kaplan-Meier showed a significant difference between the two groups ( Fig. 1) . Median time to infection from transplant was 246 and 398 days, with most infections occurring after stopping ppx. More patients in the 12 month protocol received induction and CMV immunoglobulin. While nearly all patients were on a calcineurin inhibitor, mycophenolate (MP), and prednisone at 3 months post-HT, fewer were on MP and prednisone at 6 and 12 months in the 6 month ppx cohort and more patients were on sirolimus or everolimus in the same group. Conclusion: Patients in the 6 month CMV ppx protocol had significantly higher incidence of CMV infection and hospitalization. While a longer ppx protocol may theoretically increase risk of leukopenia and financial burden, our study suggests 12 months of ppx is a better strategy when considering that hospitalization for CMV is no trivial matter.

Intravenous Immunoglobulin is Associated with Lower Rates of Reinfection in Solid Organ Recipients with Infection and Secondary Antibody Deficiency: A Multicenter Randomized Clinical Trial J. Carbone, 1 J. Montanchez, 2 J

Abstracts S179